These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11808830)

  • 21. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.
    Kovarik JM; Bartlett M; Rordorf C; Antunes MC; Winter S; Marbach P; van Marle S
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):103-8. PubMed ID: 20137762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral.
    First MR; Alloway R; Schroeder TJ
    Clin Transplant; 1998 Dec; 12(6):518-24. PubMed ID: 9850444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
    Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
    J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
    Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
    Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
    Rostaing L; Christiaans MH; Kovarik JM; Pascual J
    Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral.
    Schroeder TJ; Cho MJ; Pollack GM; Floc'h R; Moran HB; Levy R; Moore LW; Pouletty P
    J Clin Pharmacol; 1998 Sep; 38(9):807-14. PubMed ID: 9753208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S; Scavuzzo M; Chaparro C; Szalai JP
    Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients.
    Levy GA; Grant D; Paradis K; Campestrini J; Smith T; Kovarik JM
    Transplantation; 2001 Jan; 71(1):160-3. PubMed ID: 11211186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.
    Kovarik JM; Kaplan B; Silva HT; Kahan BD; Dantal J; McMahon L; Berthier S; Hsu CH; Rordorf C
    Am J Transplant; 2003 May; 3(5):606-13. PubMed ID: 12752317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.
    Neumayer HH; Paradis K; Korn A; Jean C; Fritsche L; Budde K; Winkler M; Kliem V; Pichlmayr R; Hauser IA; Burkhardt K; Lison AE; Barndt I; Appel-Dingemanse S
    Br J Clin Pharmacol; 1999 Nov; 48(5):694-703. PubMed ID: 10594471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
    Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
    Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
    Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L
    Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
    Transplant Proc; 2006 Sep; 38(7):2032-4. PubMed ID: 16979990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.
    Hausen B; Ikonen T; Briffa N; Berry GJ; Christians U; Robbins RC; Hook L; Serkova N; Benet LZ; Schuler W; Morris RE
    Transplantation; 2000 Jan; 69(1):76-86. PubMed ID: 10653384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.
    Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B
    J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
    Budde K; Lehne G; Winkler M; Renders L; Lison A; Fritsche L; Soulillou JP; Fauchald P; Neumayer HH; Dantal J;
    J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoral use in the cardiac transplant recipient.
    Valantine H
    Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.